{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:27:25Z","timestamp":1790519245495,"version":"4.1.0"},"reference-count":32,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.3892\/ol.2017.6459","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T05:01:30Z","timestamp":1498107690000},"page":"2531-2536","source":"Crossref","is-referenced-by-count":42,"title":["Clinical significance of circulating microparticles in Ph\u2212 myeloproliferative neoplasms"],"prefix":"10.3892","volume":"14","author":[{"given":"Wenjuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgeng","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"key":"key20180108115032_b1-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"key20180108115032_b2-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bjh.12308","article-title":"Inhibition of related JAK\/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm","volume":"161","author":"Barrio","year":"2013","journal-title":"Br J Haematol"},{"key":"key20180108115032_b3-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"key20180108115032_b4-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"key20180108115032_b5-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ajh.23135","article-title":"Polycythemi a vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Tefferi","year":"2012","journal-title":"Am J Hematol"},{"key":"key20180108115032_b6-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: Incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"key":"key20180108115032_b7-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythemia","volume":"132","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"key":"key20180108115032_b8-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.10634","article-title":"Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status","volume":"92","author":"Finazzi","year":"2007","journal-title":"Haematologica"},{"key":"key20180108115032_b9-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"30867","DOI":"10.18632\/oncotarget.9018","article-title":"Tumour-associated circulating microparticles: A novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia","volume":"7","author":"Willms","year":"2016","journal-title":"Oncotarget"},{"key":"key20180108115032_b10-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1007\/s13277-016-5047-5","article-title":"Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention","volume":"37","author":"Tseng","year":"2016","journal-title":"Tumour Biol"},{"key":"key20180108115032_b11-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.thromres.2016.05.021","article-title":"Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis","volume":"143","author":"Campello","year":"2016","journal-title":"Thromb Res"},{"key":"key20180108115032_b12-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCRESAHA.110.233056","article-title":"Microparticles in hemostasis and thrombosis","volume":"108","author":"Owens","year":"2011","journal-title":"Circ Res"},{"key":"key20180108115032_b13-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180108115032_b14-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/ijo.2011.19","article-title":"Short-term very low-calorie diet in obese females improves the haemostatic balance through the reduction of leptin levels, PAI-1 concentrations and a diminished release of platelet and leukocyte-derived microparticles","volume":"35","author":"Morel","year":"2011","journal-title":"Int J Obes (Lond)"},{"key":"key20180108115032_b15-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"key20180108115032_b16-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/01.HYP.0000231507.00962.b5","article-title":"Circulating microparticles: A potential prognostic marker for atherosclerotic vascular disease","volume":"48","author":"Boulanger","year":"2006","journal-title":"Hypertension"},{"key":"key20180108115032_b17-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2004-05-2042","article-title":"Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis","volume":"105","author":"Yu","year":"2005","journal-title":"Blood"},{"key":"key20180108115032_b18-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1538-7836.2008.02987.x","article-title":"Tissue factor-bearing microparticles derived from tumor cells: Impact on coagulation activation","volume":"6","author":"Davila","year":"2008","journal-title":"J Thromb Haemost"},{"key":"key20180108115032_b19-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1084\/jem.20082297","article-title":"Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo","volume":"206","author":"Thomas","year":"2009","journal-title":"J Exp Med"},{"key":"key20180108115032_b20-ol-0-0-6459","first-page":"312","article-title":"Scott syndrome: A disorder of platelet coagulant activity","volume":"31","author":"Weiss","year":"1994","journal-title":"Semin Hematol"},{"key":"key20180108115032_b21-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1160\/TH06-03-0141","article-title":"Tissue factor-positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer","volume":"97","author":"Hron","year":"2007","journal-title":"Thromb Haemost"},{"key":"key20180108115032_b22-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.thromres.2010.07.006","article-title":"Plasma levels of microparticle-associated tissue factor activity in patients with clinically suspected pulmonary embolism","volume":"126","author":"Rodriguez","year":"2010","journal-title":"Thromb Res"},{"key":"key20180108115032_b23-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00277-013-1676-6","article-title":"Increased promyelocytic-derived microparticles: A novel potential factor for coagulopathy in acute promyelocytic leukemia","volume":"92","author":"Ma","year":"2013","journal-title":"Ann Hematol"},{"key":"key20180108115032_b24-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1538-7836.2007.02369.x","article-title":"Microparticle-associated tissue factor activity: A link between cancer and thrombosis?","volume":"5","author":"Tesselaar","year":"2007","journal-title":"J Thromb Haemost"},{"key":"key20180108115032_b25-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3324\/haematol.13774","article-title":"Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia","volume":"94","author":"Trappenburg","year":"2009","journal-title":"Haematologica"},{"key":"key20180108115032_b26-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.thromres.2010.06.025","article-title":"Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms","volume":"126","author":"Duchemin","year":"2010","journal-title":"Thromb Res"},{"key":"key20180108115032_b27-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.thromres.2011.01.002","article-title":"Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism","volume":"127","author":"Campello","year":"2011","journal-title":"Thromb Res"},{"key":"key20180108115032_b28-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1756-8722-5-43","article-title":"Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors","volume":"5","author":"Randhawa","year":"2012","journal-title":"J Hematol Oncol"},{"key":"key20180108115032_b29-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clml.2011.10.002","article-title":"Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: A multicenter study from Korea","volume":"12","author":"Lee","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20180108115032_b30-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"key":"key20180108115032_b31-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"key":"key20180108115032_b32-ol-0-0-6459","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.23590","article-title":"Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia","volume":"89","author":"Marchetti","year":"2014","journal-title":"Am J Hematol"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T10:26:18Z","timestamp":1569493578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2017.6459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6,22]]},"published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.3892\/ol.2017.6459"],"URL":"https:\/\/doi.org\/10.3892\/ol.2017.6459","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]}}}